Baseline characteristics of participants and baseline FRAX® risk estimates
| All | Men | Women | |
| N, n (%) | 2626 | 683 (27) | 1943 (73.0) |
| Age, mean (SD) | 58.2 (10.2) | 60.3 (11.4) | 57.7 (9.9) |
| 40–59, n (%) | 1495 (56.9) | 352 (51.5) | 1143 (58.8) |
| 60–74, n (%) | 950 (36.2) | 260 (38.1) | 690 (35.5) |
| ≥75, n (%) | 181 (6.9) | 71 (10.4) | 110 (5.7) |
| BMI, mean (SD) | 27.3 (4.5) | 75.5 (11.9) | 66.4 (11.6) |
| Previous fracture, n (%) | 512 (19.5) | 153 (22.4) | 359 (18.5) |
| Parent hip fractures, n (%) | 213 (8.1) | 50 (7.3) | 163 (8.4) |
| Current smoking, n (%) | 612 (23.3) | 344 (50.4) | 268 (13.8) |
| Oral glucocorticoids, n (%) | 182 (6.9) | 38 (5.6) | 144 (7.4) |
| Rheumatoid arthritis, n (%) | 128 (4.9) | 18 (2.6) | 110 (5.7) |
| Secondary osteoporosis, n (%) | 639 (24.3) | 46 (6.7) | 593 (30.5) |
| Alcohol three or more units day, n (%) | 529 (20.1) | 287 (42) | 242 (12.5) |
| Femoral neck T score, mean (SD)* | −1.54 (1.31) | −1.35 (1.40) | −1.58 (1.30) |
| ≥ −1, n (%) | 595 (31.4) | 138 (37.7) | 457 (29.9) |
| −2.5<T<−1, n (%) | 867 (45.7) | 152 (41.5) | 715 (46.7) |
| ≤−2.5, n (%) | 435 (22.9) | 76 (20.8) | 359 (23.4) |
| Median 10 year probability, median (IQR) | |||
| MOP fracture without BMD | 2.9 (1.7–5.8) | 1.6 (1.6–4.4) | 3.0 (1.7–6.2) |
| MOP fracture with BMD | 3.4 (1.8–6.9) | 3.1 (1.7–6) | 3.5 (1.9–7) |
| Hip fracture without BMD | 0.5 (0.2–1.6) | 0.5 (0.2–1.6) | 0.5 (0.2–1.6) |
| Hip fracture with BMD | 0.7 (0.2–2.5) | 0.95 (0.28–2.93) | 0.6 (0.2–2.3) |
There were no missing data for any of the clinical risk factors considered by FRAX®.
*Femoral Neck BMD was available for 1897 participants.
BMD, bone mineral density; BMI, body mass index; MOP, major osteoporotic.